Onconova Therapeutics to Attend the Sachs 21st Annual Biotech in Europe Forum (BEF)

Rhea-AI Summary

Onconova Therapeutics (NASDAQ: ONTX) announced participation in the Sachs 21st Annual Biotech in Europe Forum on October 7-8, 2021. Management will be available for 1x1 meetings from October 4-8, 2021, via the Sachs Event portal.

Onconova is focused on developing novel cancer treatments, including the multi-kinase inhibitor ON 123300 in Phase 1 studies in the U.S. and China. Additionally, rigosertib is being explored in a combo treatment for KRAS+ non-small cell lung cancer.

NEWTOWN, Pa., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will be attending the upcoming virtual Sachs 21^st Annual Biotech in Europe Forum (BEF) on October 7^th and 8^th 2021, and will be available for 1x1 meetings from Monday, October 4^th through Friday, October 8^th.   Those registered for the event can request a meeting with Onconova through the Sachs Event’s portal.

About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-initiated study program, including in a dose-escalation and expansion Phase 1/2a investigator-initiated study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit www.onconova.com.

Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova’s expectations regarding the timing of Onconova’s and investigator-initiated clinical development and data presentation plans, and the mechanisms and indications for Onconova’s product candidates. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “preliminary,” “encouraging,” "approximately" or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova's clinical trials, investigator-initiated trials and regulatory agency and institutional review board approvals of protocols, Onconova’s collaborations, market conditions and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com

FAQ

When is the Sachs 21st Annual Biotech in Europe Forum for Onconova Therapeutics?

Onconova Therapeutics will participate in the Sachs 21st Annual Biotech in Europe Forum on October 7-8, 2021.

What is ON 123300, and what is its current status?

ON 123300 is a novel multi-kinase inhibitor being studied in ongoing Phase 1 trials in the U.S. and China.

What studies is Onconova conducting for rigosertib?

Rigosertib is being evaluated in a Phase 1/2a investigator-initiated study in combination with nivolumab for KRAS+ non-small cell lung cancer.

How can investors request meetings with Onconova during the Sachs Event?

Investors can request meetings with Onconova through the Sachs Event’s portal from October 4-8, 2021.